ライフサイエンスコーパス: tumor-promoting

1 a signaling shifts from tumor suppressive to tumor promoting.

2 mediated signaling from tumor suppressive to tumor promoting.

3 hat loss of NF-kappaB activity or IKKbeta is tumor promoting.

4 lymphatic vessels and macrophages to be less tumor promoting.

5 or-beta (TGF-beta) from tumor-suppressing to tumor-promoting.

6 eous skin tumors and are highly sensitive to tumor-promoting 7,12-dimethylbenzanthracene/12-O-tetrade

7 er cell proliferation and account for IMP2's tumor promoting action.

8 Together, the dual host-protective and tumor-promoting actions of immunity are referred to as c

9 PLA(2) activities correlated with tumor-promoting activates in cell-based and in vivo assa

10 -suppressing (apoptosis regulation) but also tumor-promoting activities (enhancer of mitotic entry).

11 Inflammatory cytokines such as IL-6 exert tumor-promoting activities by driving growth and surviva

12 The cytokine IL6 has a number of tumor-promoting activities in human and experimental can

13 ribute to the opposing tumor-suppressive and tumor-promoting activities of these PKC family members i

14 ponent of the tumor stroma and exert several tumor-promoting activities.

15 kine production, inflammatory responses, and tumor-promoting activities.

16 ed recruitment of macrophages with prominent tumor-promoting activities.

17 s acts as a fail-safe mechanism to limit the tumor promoting activity of AID when it overwhelms uraci

18 rs, such as NF-kappaB and STAT3, exert their tumor-promoting activity at least in part through upregu

19 These findings suggest a novel pathway of tumor-promoting activity by Ror2 within a subset of rena

20 Here, we investigated its tumor-promoting activity by use of a mouse orthotopic pr

21 inflammatory IL6 has both local and systemic tumor-promoting activity in many cancers, including ovar

22 Overall, our results reveal an unexpected tumor-promoting activity of activated NRF2 during early

23 hose of wild-type cells, suggesting that the tumor-promoting activity of ADAM12-S was a function of i

24 quitination and degradation, thus inhibiting tumor-promoting activity of AP-1.

25 r of actin dynamics, as a determinant of the tumor-promoting activity of ASCs.

26 cancer development, as a determinant for the tumor-promoting activity of cancer-associated fibroblast

27 The tumor-promoting activity of epithelial p38gamma was furt

28 Ms is downstream of FLT1 and can restore the tumor-promoting activity of FLT1-inhibited MAMs.

29 y concurrent LSD1 depletion, indicating that tumor-promoting activity of HDAC5 is an LSD1 dependent f

30 t IL-17 was required for the development and tumor-promoting activity of MDSCs in tumor-bearing mice.

31 of this residue to phenylalanine reduced the tumor-promoting activity of p21 in the animal model, whe

32 with the in vivo data demonstrating a strong tumor-promoting activity of PRR14 and the mutants, our w

33 signaling is a major pathway regulating the tumor-promoting activity of TGF-beta.

34 ating that VN binding is responsible for the tumor-promoting activity of uPAR in vivo.

35 tly needed to investigate how to inhibit the tumor-promoting activity of WAT cells and progenitors.

36 Par3 mediates its tumor-promoting activity through regulation of growth an

37 id metabolism is distinct and separable from tumor-promoting activity.

38 mor microenvironment could contribute to its tumor-promoting activity.

39 pressors also target CtBPs to restrain their tumor-promoting activity.

40 Our data indicate that CD44 is a key tumor-promoting agent in transformed tumor cells lacking

41 ent is elicited by repeated treatment with a tumor-promoting agent.

42 emonstrate an important role for JNK2 in the tumor promoting an invasive capacity of EGFR variant III

43 special focus on the metabolic modulation of tumor promoting and suppressing pathways and, conversely

44 er is not understood, as both AMPK-dependent tumor-promoting and -inhibiting functions were reported.

45 ptors, and discuss the evidence for DAMPs as tumor-promoting and anti-tumor effectors, as well as uns

46 ssed here how it is regulated in response to tumor-promoting and antigen-mimicking signals.

47 we describe that TAMs require ZEB1 for their tumor-promoting and chemotherapy resistance functions in

48 Also, four members of the tumor-promoting and HSF1-associated phosphatidylinositol

49 , our studies suggest that inhibition of the tumor-promoting and immune-suppressive functions of MDSC

50 We also review the tumor-promoting and tumor-suppressing consequences of W-

51 epigenetic modifications that can have both tumor-promoting and tumor-suppressing effects.

52 The balance between tumor-promoting and tumor-suppressing immune responses a

53 CXCR2 has been suggested to have both tumor-promoting and tumor-suppressive properties.

54 t least in part, through modulating multiple tumor-promoting autocrine/paracrine factors.

55 n of AR3 modulates expression of a number of tumor-promoting autocrine/paracrine growth factors (incl

56 iators accompanied by aberrant activation of tumor-promoting c-JUN and STAT3 signaling cascades, and

57 and SDF-1 autocrine signaling gives rise to tumor-promoting CAF myofibroblasts during tumor progress

58 ormal tissue fibroblasts are reprogrammed to tumor-promoting CAFs are mainly obscure.

59 ntin in reprograming normal fibroblasts into tumor-promoting CAFs.

60 therapeutic target to block the evolution of tumor-promoting CAFs.

61 gumain, is highly expressed in various solid tumors, promoting cancer cell invasion, migration, and m

62 cell carcinoma (OSCC) that have differential tumor-promoting capability, one with a transcriptome and

63 ols, we show that NKG2D self-stimulation has tumor-promoting capacity.

64 ical for macrophage populations with reduced tumor-promoting capacity.

65 ing a therapeutic approach for reducing this tumor-promoting cell population.

66 of genetic changes to the tumor cell or the tumor-promoting cell.

67 version of progenitor smooth muscle cells to tumor-promoting cells.

68 at tumorigenesis occurs when tissue-specific tumor-promoting changes are formed through these events.

69 r microenvironment and is accompanied by key tumor-promoting changes in the extracellular matrix prot

70 e histone methyltransferase Setd2 had robust tumor-promoting consequences.

71 uced influx of leukocytes and down regulated tumor-promoting cyto-/chemokine profile in bronchoalveol

72 own-regulated the synthesis and secretion of tumor-promoting cytokines and chemokines into the bronch

73 in Itch or Cyld led to chronic production of tumor-promoting cytokines by tumor-associated macrophage

74 was dependent on enhanced production of the tumor-promoting cytokines IL-6 and TNF, which cause hepa

75 Expression and secretion of multiple tumor-promoting cytokines or chemokines in the liver wer

76 expression of T-cell exhaustion markers and tumor-promoting cytokines.

77 l mice display elevation of SK1 levels and a tumor-promoting dysregulation of bioactive sphingolipids

78 The tumor promoting effect of PKCalpha loss was reflected in

79 Interestingly, this tumor-promoting effect by p53-deficient MSCs was not obs

80 n of other regulators; therefore, this FOG-3 tumor-promoting effect is context dependent.

81 We further showed that the transmission of tumor-promoting effect is partially mediated by soluble

82 -mediated and HBsTg-driven HCG, suggesting a tumor-promoting effect of BID.

83 elevated CCL-2 expression in BM-L-MSCs, the tumor-promoting effect of BM-L-MSCs largely depends on C

84 une functions of complement proteins and the tumor-promoting effect of complement activation.

85 clodronate-containing liposomes blocked the tumor-promoting effect of DNFB.

86 These findings suggest that the tumor-promoting effect of E-cadherin suppression, a comm

87 1 in response to stress, indicating that the tumor-promoting effect of E2F7/8 inactivation can be par

88 We demonstrated the tumor-promoting effect of hypoxia on tumor initiation in

89 and on mechanisms that may contribute to the tumor-promoting effect of MCs in animals, including the

90 To validate the tumor-promoting effect of miR-221, we showed that in viv

91 an lung carcinoma H460 cells, suggesting the tumor-promoting effect of PMMTM.

92 Unexpectedly, the tumor-promoting effect of tissue injury also requires c-

93 the mechanisms underlying the DcR3-mediated tumor-promoting effect remain unclear.

94 Furthermore, we localized the tumor-promoting effect to a 115-amino acid region in sec

95 roduction and anti-IL-23 mAbs to counter the tumor promoting effects of IL-23 has greater antitumor a

96 Interestingly, the mammary tumor-promoting effects of a Cav-1-deficient microenviro

97 CXCR2 silencing in CSCs abolished the tumor-promoting effects of endothelial cells in vivo, co

98 Mechanistically, we attributed the tumor-promoting effects of Ikkepsilon to limited TNF-dep

99 for Akt and Erk activation in mediating the tumor-promoting effects of IL4Ralpha.

100 rophage integrin beta3 signaling blocked the tumor-promoting effects of integrin beta3 antagonism.

101 Mechanistic studies showed that these tumor-promoting effects of macrophages are through the s

102 Mechanistic investigations revealed that the tumor-promoting effects of Nestin were mediated by bindi

103 Conclusion The tumor-promoting effects of obesity occur at the local le

104 Among the mechanisms implicated in the tumor-promoting effects of obesity, signaling by insulin

105 We show the dependency of the tumor-promoting effects of PTEN on mut-p53 by showing th

106 mut-p53 expression inhibits or reverses the tumor-promoting effects of PTEN.

107 orm-specific binding proteins to clarify the tumor-promoting effects of RhoA and C that contrast with

108 Tumor-promoting effects of T2D in the models were revers

109 Our findings suggest that indirect tumor-promoting effects of testosterone likely explain t

110 to the immunosuppressive, proangiogenic, and tumor-promoting effects of this pleiotropic effector in

111 evealed that FGF1 is sufficient to drive the tumor-promoting effects of WNT7A.

112 ell population through apoptosis could yield tumor-promoting effects.

113 ation in the tumor microenvironment has many tumor-promoting effects.

114 tion of MDSCs is a primary mechanism for its tumor-promoting effects.

115 capacity, whereas TAMs of M2 phenotype exert tumor-promoting effects.

116 o, whereas PEDF-depleted fibroblasts exerted tumor-promoting effects.

117 atment of V33 Apc (Min/+) mice abrogated the tumor promoting-effects of IL-33 in the colon.

118 ntestinal lamina propria, thereby favoring a tumor-promoting environment.

119 colon tumor pathogenesis, as well as work on tumor-promoting environmental factors and agents and str

120 e that the sun's harmful rays may also cause tumor-promoting epigenetic modifications in dermal fibro

121 As UVB-induced inflammation is an important tumor-promoting event in the development of skin tumors,

122 Further tumor promoting events are required to unleash their car

123 way in non-FA human tumor cells and act as a tumor promoting factor.

124 ozygous microdeletions, PDE4D functions as a tumor-promoting factor and represents a unique targetabl

125 ted recruitment of neutrophils secreting the tumor-promoting factor APRIL mediates DLBCL progression.

126 Lysophosphatidic acid (LPA), a major tumor-promoting factor in EOC ascites, is an enzymatic p

127 When a large number of tumor-promoting factors are present in a strain, the pro

128 esized that autophagy-dependent secretion of tumor-promoting factors by HNSCC-associated CAFs may exp

129 However, when the dosage of tumor-promoting factors is reduced, the protective effec

130 lular source influences the function of such tumor-promoting factors remains an open question.

131 Taken together, our data support the tumor promoting function of Cx-43 in melanoma.

132 usive cancer targets despite the unambiguous tumor promoting function of their potent ligands, phorbo

133 at cytoplasmically localized RB may harbor a tumor promoting function.

134 results indicated that miR-21/AR mediate its tumor-promoting function by attenuating TGFbeta-mediated

135 In contrast, we have uncovered a potent tumor-promoting function for Arkadia.

136 These results identify a novel tumor-promoting function for IGFBP2 of activating EGFR/S

137 Our findings reveal a non-cell-intrinsic, tumor-promoting function for Tet2 and suggest that Tet2

138 Cell-based studies suggest a tumor-promoting function for the SphK1/S1P pathway.

139 Our results establish a tumor-promoting function for Treg during CAC formation,

140 We provide evidence that the tumor-promoting function of BID in CLI is not related to

141 RalA executes this tumor-promoting function of dermal fibroblasts, at least

142 The tumor-promoting function of lal(-/-) MDSCs is mediated,

143 mediators responsible for expansion and the tumor-promoting function of MDSCs, we discovered CCAAT/e

144 ions as a tumor suppressor by inhibiting the tumor-promoting function of PPARgamma, which triggers an

145 ur findings reveal a previously unrecognized tumor-promoting function of RNF8 and provide evidence th

146 whereas lower levels are sufficient for the tumor promoting functions.

147 is beginning to emerge, with the notion that tumor-promoting functions are attributed to its products

148 Interestingly, several of the tumor-promoting functions of CtsZ were not dependent on

149 nsatory protease that regulates the acquired tumor-promoting functions of lesions deficient in both C

150 ytoplasmic domain, Y1494, contributes to the tumor-promoting functions of the alpha6beta4 integrin in

151 e demonstrate that the tumor-suppressing and tumor-promoting functions of the p38-PRAK pathway are te

152 s on their immune-suppressive activities and tumor-promoting functions, as well as the relevance to p

153 ving TAMs, which is consistent with impaired tumor-promoting functions.

154 r microenvironment and for maintaining TAMs' tumor-promoting functions.

155 (YBX1) is a well known oncoprotein that has tumor-promoting functions.

156 tinct and highly divergent cell adhesion and tumor-promoting functions.

157 a common theme in human tumors, suggesting a tumor-promoting gain-of-function for mutant p53.

158 ted kinase 1A, was a potent megakaryoblastic tumor-promoting gene that contributed to leukemogenesis

159 We hypothesized that TC-PTP may be a tumor-promoting gene that is regulated by MYC overexpres

160 nism by which LMP1 drives expression of host tumor-promoting genes by blocking generation of the inhi

161 for HSF1 in promoting mRNA transcription of tumor-promoting genes has been suggested, it appears tha

162 These stress-responsive and tumor-promoting genes in turn alter the ability of tumor

163 d HCC, resulting in the induction of various tumor-promoting genes, including indoleamine 2,3-dioxyge

164 ndogenous ligand anandamide, and a number of tumor-promoting genes, including the GRB2 interactome as

165 se that loss of CTCF-dependent imprinting of tumor-promoting genes, such as IGF2 and TERT, results fr

166 uced condition, respectively, and may act as tumor-promoting genes.

167 esis of enhancer RNAs, and the activation of tumor-promoting genes.

168 y hijacked proangiogenic, immune-evasive and tumor-promoting genes.

169 leading to enhanced translation of numerous tumor-promoting genes.

170 PIK3Cbeta(D1067V) might function as a novel tumor-promoting genetic alteration, and potentially an o

171 plays a critical role in perpetuating these tumor-promoting hallmarks but also in developing antitum

172 hich tumor cells secrete Hh ligand to induce tumor-promoting Hh target genes in adjacent stroma.

173 tumors; whereas low rates of CIN are weakly tumor promoting, higher rates of CIN cause cell death an

174 sm by which LMP1 regulates the expression of tumor-promoting host genes.

175 de cortex, interact with B cells, and foster tumor-promoting humoral immunity.

176 EAC arise from gastric progenitors due to a tumor-promoting IL-1beta-IL-6 signaling cascade and Dll1

177 rleukin [IL] 10, CC chemokine ligand 18) and tumor-promoting (IL-6, IL-8) cytokines.

178 ors; however, their presence and role in the tumor-promoting, immune-suppressive microenvironment in

179 C is tumor suppressive and its mutations are tumor promoting in ccRCC.

180 ophagy can be neutral, tumor-suppressive, or tumor-promoting in different contexts.

181 rate that CD14-high BC cells may orchestrate tumor-promoting inflammation and drive tumor cell prolif

182 lso increasingly recognized as regulators of tumor-promoting inflammation and promoters of tumor surv

183 et of TLR9/STAT3-regulated genes involved in tumor-promoting inflammation and revascularization.

184 CAF also orchestrate tumor-promoting inflammation in multiple tumor types, in

185 sponses initiated via this receptor generate tumor-promoting inflammation or antitumor immunity remai

186 Importantly, we found similar tumor-promoting inflammation surrounding the SCC in our

187 While attenuating tumor-promoting inflammation, autophagy enhances the pro

188 clude developing strategies for neutralizing tumor-promoting inflammation, broadening T-cell repertoi

189 Complement-dependent, macrophage-sustained, tumor-promoting inflammation.

190 c stellate cells, and are a key component of tumor-promoting inflammation.

191 owth of surviving malignant cells by fueling tumor-promoting inflammation.

192 ia the IL-22 receptor, resulting in enhanced tumor-promoting inflammation.

193 ndin E2, which suppresses immunity and fuels tumor-promoting inflammation.

194 ox based on cell death-mediated induction of tumor promoting inflammatory cytokines, which enhance ce

195 show that this is not due to differences in tumor-promoting inflammatory changes or variability in i

196 ellular senescence, which was accompanied by tumor-promoting inflammatory cytokine expression and acq

197 ts behind the mechanisms that establish this tumor-promoting inflammatory microenvironment remain und

198 will be an important mechanism to dampen the tumor-promoting inflammatory response and inhibit cancer

199 than suppress focal mastocytosis, a critical tumor-promoting inflammatory response.

200 Thus, suggesting a tumor-promoting influence on a broad range of CRC.

201 sure (or GSK-3beta inhibition) is blocked by tumor-promoting isoforms of APC that reduce an interacti

202 emokine receptor that directs recruitment of tumor-promoting leukocytes into tissues during tumor-ind

203 scade, the recruitment and activity of other tumor-promoting leukocytes, and tumor responses to front

204 our results demonstrate that PRL constrains tumor-promoting liver inflammation by inhibiting MAP3K-d

205 found 3 congenic strains that each harbored tumor promoting loci that had high (14%-32%) whereas 2 o

206 an important subset of immunosuppressive and tumor-promoting lymphocytes.

207 a mechanism for macrophage polarization into tumor-promoting M2 cells.

208 noma and breast cancer growth with increased tumor-promoting M2 macrophages and decreased CD8(+) T ce

209 est that a chemotherapy-mediated increase in tumor-promoting M2 macrophages may form an indirect mech

210 nown to skew differentiation of monocytes to tumor-promoting M2 macrophages.

211 ent macrophages showed a propensity toward a tumor-promoting M2 polarization, indicating a secondary

212 stimulate polarization of macrophages into a tumor-promoting M2-state and enhance the proliferation o

213 environment and their differentiation toward tumor-promoting M2-type macrophages via inhibition of ca

214 vironment; the potential to "re-educate" the tumor-promoting macrophage population may prove an effec

215 Complement activation, CCL2 production, and tumor-promoting macrophage recruitment.

216 ding an optimal probe for PET imaging of the tumor-promoting macrophage subpopulation in the tumor st

217 microenvironment showed high infiltration of tumor-promoting macrophages with high expression of the

218 ma cells not only activate expression of the tumor-promoting matrix metalloproteinases MMP2 and MMP12

219 C development and may constitute the primary tumor-promoting mechanism through which TCS acts.

220 developmental pathways is a well-recognized tumor-promoting mechanism.

221 clear causal role in cancer development, the tumor-promoting mechanisms of IGFBP2 are poorly understo

222 in the induction of an immunosuppressive and tumor-promoting microenvironment of CLL.

223 diovascular disease, and fibrosis and in the tumor-promoting microenvironment.

224 n of STAT3 target genes, and inhibition of a tumor-promoting microenvironment.

225 e tumor development through the induction of tumor-promoting microenvironments at tumor sites.

226 munication in cancer, including by conveying tumor-promoting microRNAs between cells, but their regul

227 Using a tumor-promoting model combining chronic Helicobacter hep

228 renders neoplastic growth and translation of tumor-promoting mRNAs refractory to mTOR inhibition.

229 ation of highly structured proliferation and tumor-promoting mRNAs.

230 hLAL expression reduced tumor-promoting myeloid-derived suppressive cells in the

231 on in lung epithelial cells not only reduced tumor-promoting myeloid-derived suppressor cells in the

232 mechanisms by which these cells evolve into tumor-promoting myofibroblasts remain unclear.

233 enous oxygenation products may each affect a tumor-promoting nuclear factor-kappaB activation, wherea

234 s of esophageal SCC, shedding light upon the tumor promoting oncogenic aspect of Notch1 in SCC.

235 the behavior of neoplastic cells in either a tumor-promoting or tumor-inhibiting manner.

236 regions throughout the genome, which include tumor-promoting or tumor-suppressing genes, respectively

237 monstrate a global overlap in the binding of tumor-promoting p53 mutants and the master proinflammato

238 A CDK8 inhibitor suppresses damage-induced tumor-promoting paracrine activities of tumor cells and

239 ls to metformin leads to hypermethylation of tumor-promoting pathway genes and concomitant inhibition

240 tch of TGFbeta from a tumor-suppressive to a tumor-promoting pathway in pancreatic cancer.

241 A strategy for disrupting this tumor-promoting pathway is silencing TGF-beta by siRNA.

242 results suggest that Id-1 regulates multiple tumor-promoting pathways in glioblastoma and that drugs

243 table; therefore, epigenetic deregulation of tumor-promoting pathways is required for tumorigenesis.

244 s are overrepresented in stress response and tumor-promoting pathways.

245 lasts into myofibroblasts and the concurrent tumor-promoting phenotype.

246 e (TAM) recruitment and acquisition of an M2 tumor-promoting phenotype.

247 Forced depletion of Cx43, by tumor-promoting phorbol ester 12-O-tetradecanoylphorbol-

248 suggested its participation in the action of tumor-promoting phorbol esters like 12-O-tetradecanoylph

249 rine/threonine kinases are major targets for tumor-promoting phorbol esters, G protein-coupled recept

250 sed in cells stimulated by growth factors or tumor-promoting phorbol esters, we analyzed its role in

251 ST6Gal-I activity augments the expression of tumor-promoting pNFkappaB transcriptional targets such a

252 naling under glucose shortage to amplify its tumor-promoting potential.

253 naling arms, and thereby conserve or enhance tumor-promoting processes.

254 Our data indicate that PINK1 has tumor-promoting properties and demonstrates a new functi

255 s on global gene expression and suppress CAF tumor-promoting properties in an in vivo model of squamo

256 bility and resistance upon therapy, and have tumor-promoting properties in in vivo models.

257 ve stroma co-evolves with cancer, exhibiting tumor-promoting properties.

258 feature of AEG-1 that may contribute to its tumor-promoting properties.

259 ime, that the tumor suppressor PTEN can have tumor-promoting properties.

260 gely neglected for ACT due to their reported tumor-promoting properties.

261 itive regulator of MDM2, consistent with its tumor-promoting property as knockdown of NFATc3 retarded

262 Knocking down NLRP1 revealed a tumor-promoting property of NLRP1 both in vitro and in v

263 ma resident MSCs (L-MSCs) are able to confer tumor-promoting property to the naive cocultured BM-MSCs

264 and regulate protein phosphatase 4 (PP4), a tumor-promoting protein, but not the related protein pho

265 imultaneous with increased expression of the tumor-promoting protein, osteopontin (OPN).

266 ries harbor genes with putative synergistic, tumor-promoting relationships.

267 e cells are activated to signal via multiple tumor-promoting reparatory, trophic, angiogenic, tissue

268 type-specific key regulator and uncovered a tumor promoting role of IRF5.

269 ma and colon and breast cancer, suggesting a tumor-promoting role for C3aR signaling in a range of tu

270 Our findings establish a tumor-promoting role for TCF7L1 in skin and elucidate th

271 ecedes and promotes metastasis, indicating a tumor-promoting role for TDLN B cells.

272 previous observations are consistent with a tumor-promoting role for these cytokines, particularly C

273 demonstrate that Prx type II (PrxII) plays a tumor-promoting role in colorectal cancer by interacting

274 TPN1 transcription and implicated PTP1B in a tumor-promoting role in prostate cancer.

275 ved by other cavins such as cavin-2, and the tumor-promoting role of cavin-1 in pancreatic cancer was

276 In agreement with the ovarian tumor-promoting role of Neu5Ac, treatment with Neu5Ac-ta

277 Our study demonstrates a tumor-promoting role of NLRP1 in cancer cells.

278 Together, our results demonstrate a major tumor-promoting role of T reg cells in an autochthonous

279 ted alternative splicing is essential to the tumor-promoting role of TGF-beta and has a global influe

280 in cis, and we present evidence supporting a tumor-promoting role.

281 tumor models, granulocytes appear to play a tumor-promoting role.

282 on these data, it appears that OPG may have tumor-promoting roles in the pathogenesis of lymphangiol

283 tudies have identified tumor-restricting and tumor-promoting roles of PDAC-associated desmoplasia, su

284 , we evaluate the evidence to support direct tumor-promoting roles of these cytokines.

285 address both potential tumor-suppressive and tumor-promoting roles.

286 the immune system's dual host-protective and tumor-promoting roles.

287 upporting stroma and with well characterized tumor-promoting roles.

288 Paradoxically, expression of tumor-promoting simian virus 40 small tumor antigen (ST)

289 to the tumor stroma, and that recruitment of tumor-promoting spleen-derived TAMs required signaling o

290 Although the tumor-promoting Stat3 transcription factor was unaltered

291 ep stromal cells in an immunosuppressive and tumor-promoting state.

292 Indeed, Wnt5a overexpression associated with tumor-promoting stem-like characteristics (TPC) in defin

293 Preventing the accumulation of tumor-promoting T cells or enhancing the recruitment of

294 s the differentiation of CD4(+) T cells into tumor-promoting T helper type 2 cell (Th2 cell), Th17 ce

295 uence of the tumor microenvironment regulate tumor-promoting Th2 inflammation in PDAC, helping in ill

296 as shown to switch macrophage phenotype from tumor promoting to tumor suppressing.

297 g tumor-associated macrophage phenotype from tumor-promoting to tumor-suppressive status; using cellu

298 that ST6Gal-I induced expression of the key tumor-promoting transcription factors, Sox9 and Slug.

299 ivation, and by polarizing immunity toward a tumor-promoting type 2 phenotype.

300 cing factor CAPERalpha regulates splicing of tumor-promoting VEGF isoforms, yet the molecular target